Newsroom

GLG Pharma’s STAT3 Signaling Inhibitor Selected for NCI’s PREVENT Cancer Preclinical Drug Development Program 7.22.13

  Jupiter, Florida July 16, 2013- GLG Pharma, LLC announces scientific and financial resources of the PREVENT Cancer program of the National Cancer Institute of the NIH have been approved to study the effects of its STAT3 signaling inhibitor, GLG-302 as a breast cancer chemopreventive. The...

Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 7.16.13

  Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy —Data Presented at AED Xll Meeting Confirms INS001 Appears Safe and Well Tolerated  —Preparations for Phase II Proof of Principle Trial Underway—   MIAMI, May 17, 2013 /PRNewswire/ -- Insero Health...

Florida Institute Funds ClearSpec Medical 7.11.13

  Boca Raton- Based ClearSpec Medical Receives Florida Institute Funding Seed Funds to Advance Device Development and Commercialization Efforts Gainesville and Boca Raton, FL – July 11, 2013 - The Institute for Commercialization of Public Research (the Institute) announced today that it has...

Share

Facebook icon
Twitter icon
LinkedIn icon
Pinterest icon
e-mail icon